These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25627832)

  • 21. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiences with adverse drug reaction reporting by patients: an 11-country survey.
    van Hunsel F; Härmark L; Pal S; Olsson S; van Grootheest K
    Drug Saf; 2012 Jan; 35(1):45-60. PubMed ID: 22149419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do pharmacists' reports of adverse drug reactions reflect patients' concerns?
    van Grootheest K; van Puijenbroek EP; de Jong-van den Berg LT
    Pharm World Sci; 2004 Jun; 26(3):155-9. PubMed ID: 15230363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example.
    van Hunsel F; Passier A; van Grootheest K
    Br J Clin Pharmacol; 2009 May; 67(5):558-64. PubMed ID: 19552751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
    Holm L; Ekman E; Jorsäter Blomgren K
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
    Jarernsiripornkul N; Patsuree A; Krska J
    Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Qualitative Study of General Public Views towards Adverse Drug Reactions in Lithuania.
    Valinciute-Jankauskiene A; Loreta K
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33803215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bias in spontaneous reporting of adverse drug reactions in Japan.
    Matsuda S; Aoki K; Kawamata T; Kimotsuki T; Kobayashi T; Kuriki H; Nakayama T; Okugawa S; Sugimura Y; Tomita M; Takahashi Y
    PLoS One; 2015; 10(5):e0126413. PubMed ID: 25933226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects.
    Boer J; Ederveen E; Grundmark B
    Ups J Med Sci; 2018 Sep; 123(3):174-178. PubMed ID: 30084285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.
    Ji Y; Ying H; Farber MS; Yen J; Dews P; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2010 May; 14(3):826-37. PubMed ID: 20007038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs.
    Matos C; Härmark L; van Hunsel F
    Drug Saf; 2016 Nov; 39(11):1105-1116. PubMed ID: 27581398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk.
    Wechwithan S; Suwankesawong W; Sornsrivichai V; McNeil EB; Jiraphongsa C; Chongsuvivatwong V
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):407-12. PubMed ID: 24945744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.